NERV News and Press, Minerva Neurosciences Inc From 05/01/23

2023-05-01 10:03:58 ET Gainers: Nano-X Imaging ( NNOX ) +53% . Meihua International Medical Technologies ( MHUA ) +34% .  Minerva Neurosciences ( NERV ) +27% . Apollomics ( APLM ) +24% . Ascendis Pharma ( ASND ) +19% . ...

2023-05-01 08:28:28 ET Minerva Neurosciences ( NASDAQ: NERV ) said the U.S. Food and Drug Administration (FDA) filed the company's new drug application (NDA) for roluperidone to treat negative symptoms in patients with schizophrenia. The decision to file the NDA follows Minerv...

BURLINGTON, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) ...

2023-04-26 10:09:11 ET Gainers: Scilex Holding ( SCLX ) +14% . Cytek Biosciences ( CTKB ) +12% . Minerva Neurosciences ( NERV ) +10% . Vincerx Pharma ( VINC ) +9% . LianBio ( LIAN ) +7% . Losers: ZyVersa Therapeutics ( Z...

2023-03-08 11:31:09 ET Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Fred Ahlholm - CFO Conference Call Participants Andrew Tsai - Jefferi...

2023-03-08 07:31:55 ET Minerva Neurosciences press release ( NASDAQ: NERV ): Q4 GAAP EPS of -$1.26 misses by $0.34 . Cash, cash equivalents, and restricted cash as of December 31, 2022 were approximately $36.2 million, compared to $60.9 million as of December 31, 2021....

BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth ...

BURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release fiscal year 2022 financial...

Minerva Neurosciences ( NASDAQ: NERV ) said that following a Type A meeting held on Nov. 30, the U.S. Food and Drug Administration (FDA) confirmed that the agency's refusal to review the company's application for roluperidone to treat negative symptoms in patients with schizophre...

BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that, following the Type A meeting held on Novem...